2023-09-01 2024-08-31 false Capium Accounts Production 1.1 14326405 2023-09-01 2024-08-31 14326405 bus:FullAccounts 2023-09-01 2024-08-31 14326405 bus:FRS102 2023-09-01 2024-08-31 14326405 bus:AuditExemptWithAccountantsReport 2023-09-01 2024-08-31 14326405 bus:SmallCompaniesRegimeForAccounts 2023-09-01 2024-08-31 14326405 bus:PrivateLimitedCompanyLtd 2023-09-01 2024-08-31 14326405 2023-09-01 2024-08-31 14326405 2024-08-31 14326405 bus:RegisteredOffice 2023-09-01 2024-08-31 14326405 core:WithinOneYear 2024-08-31 14326405 core:AfterOneYear 2024-08-31 14326405 1 2023-09-01 2024-08-31 14326405 bus:Director1 2023-09-01 2024-08-31 14326405 bus:Director1 2024-08-31 14326405 bus:Director1 2022-09-01 2023-08-31 14326405 2022-09-01 14326405 bus:LeadAgentIfApplicable 2023-09-01 2024-08-31 14326405 2022-09-01 2023-08-31 14326405 2023-08-31 14326405 core:WithinOneYear 2023-08-31 14326405 core:AfterOneYear 2023-08-31 14326405 bus:EntityAccountantsOrAuditors 2022-09-01 2023-08-31 14326405 core:MotorCars 2023-09-01 2024-08-31 14326405 core:MotorCars 2024-08-31 14326405 core:MotorCars 2023-08-31 14326405 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-08-31 14326405 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-08-31 14326405 core:CostValuation core:Non-currentFinancialInstruments 2024-08-31 14326405 core:CostValuation core:Non-currentFinancialInstruments 2023-08-31 14326405 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-08-31 14326405 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-08-31 14326405 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-08-31 14326405 core:Non-currentFinancialInstruments 2024-08-31 14326405 core:Non-currentFinancialInstruments 2023-08-31 14326405 core:ShareCapital 2024-08-31 14326405 core:ShareCapital 2023-08-31 14326405 core:RetainedEarningsAccumulatedLosses 2024-08-31 14326405 core:RetainedEarningsAccumulatedLosses 2023-08-31 14326405 core:ShareCapitalOrdinaryShares 2023-09-01 14326405 core:ShareCapitalOrdinaryShares 2022-09-01 14326405 core:ShareCapitalOrdinaryShares 2023-09-01 2024-08-31 14326405 core:ShareCapitalOrdinaryShares 2022-09-01 2023-08-31 14326405 core:ShareCapitalOrdinaryShares 2024-08-31 14326405 core:ShareCapitalOrdinaryShares 2023-08-31 14326405 core:RetainedEarningsAccumulatedLosses 2023-09-01 14326405 core:RetainedEarningsAccumulatedLosses 2022-09-01 14326405 core:RetainedEarningsAccumulatedLosses 2023-09-01 2024-08-31 14326405 core:RetainedEarningsAccumulatedLosses 2022-09-01 2023-08-31 14326405 core:RetainedEarningsAccumulatedLosses 2024-08-31 14326405 core:RetainedEarningsAccumulatedLosses 2023-08-31 14326405 dpl:Item1 2023-09-01 14326405 dpl:Item1 2024-08-31 14326405 dpl:Item1 2022-09-01 14326405 dpl:Item1 2023-08-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 14326405
England and Wales

 

 

 

QSEM PHARMA LTD



Unaudited Financial Statements
 


Period of accounts

Start date: 01 September 2023

End date: 31 August 2024
Director Imran Ashraf
Registered Number 14326405
Registered Office 528 Forest Road
London
E17 4NB
1
Director's report and financial statements
The director presents his/her/their annual report and the financial statements for the year ended 31 August 2024.
Principal activities
Principal activity of the company during the financial year was of pharmaceutical consultancy services.
Director
The director who served the company throughout the year was as follows:
Imran Ashraf
Statement of director's responsibilities
The director is responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations and in accordance with United Kingdom Generally Accepted Accounting Practice.
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.
In preparing these financial statements, the director is required to :
  • select suitable accounting policies and then apply them consistently
  • make judgements and accounting estimates that are reasonable and prudent
  • state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements and
  • prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The director is responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom, governing the preparation and dissemination of financial statements, may differ from legislation in other jurisdictions

On behalf of the board.


----------------------------------
Imran Ashraf
Director

Date approved: 31 May 2025
2
Report to the directors on the preparation of the unaudited statutory accounts of QSEM Pharma Ltd for the year ended 31 August 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of QSEM Pharma Ltd for the year ended 31 August 2024 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company’s accounting records and from information and explanations you have given to us.

As a practising member firm of the Institute of Financial Accountants (IFA), we are subject to its ethical and other professional requirements which are detailed at https://www.ifa.org.uk/about-us/acting-in-the-public-interest/memberregulations.

This report is made solely to the Board of Directors of QSEM Pharma Ltd, as a body, in accordance with the terms of our engagement letter dated 31 May 2025. Our work has been undertaken solely to prepare for your approval the accounts of QSEM Pharma Ltd and state those matters that we have agreed to state to the Board of Directors of QSEM Pharma Ltd, as a body, in this report.To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than QSEM Pharma Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that QSEM Pharma Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit or loss of QSEM Pharma Ltd.You consider that QSEM Pharma Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit of the accounts of QSEM Pharma Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements 31 August 2024.


M & M Accountants
528 FOREST ROAD
LONDON
E17 4NB
31 May 2025
3
 
 
Notes
 
2024
£
  2023
£
Turnover 24,500    38,448 
Gross profit 24,500    38,448 
Administrative expenses (15,371)   (8,710)
Operating profit 9,129    29,738 
Profit/(Loss) on ordinary activities before taxation 9,129    29,738 
Tax on profit on ordinary activities (2,296)   (598)
Profit/(Loss) for the financial year 6,833    29,140 
 
4
 
 
Notes
 
2024
£
  2023
£
Fixed assets      
Tangible fixed assets 3 23,636    26,590 
23,636    26,590 
Current assets      
Cash at bank and in hand 24,873    36,076 
Creditors: amount falling due within one year 4 (12,535)   (33,525)
Net current assets 12,338    2,551 
 
Total assets less current liabilities 35,974    29,141 
Net assets 35,974    29,141 
 

Capital and reserves
     
Called up share capital 1    1 
Profit and loss account 35,973    29,140 
Shareholders' funds 35,974    29,141 
 


For the year ended 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 31 May 2025 and were signed by:


-------------------------------
Imran Ashraf
Director
5
  Equity share capital   Retained Earnings   Total
£ £ £
Profit for the year 29,140  29,140 
Total comprehensive income for the year 29,140  29,140 
Shares issued 1 
Total investments by and distributions to owners 1 
At 31 August 2023 1  29,140  29,141 
At 01 September 2023 1  29,140  29,141 
Profit for the year 6,833  6,833 
Total comprehensive income for the year 6,833  6,833 
Total investments by and distributions to owners
At 31 August 2024 1  35,973  35,974 
6
General Information
QSEM Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 14326405, registration address 528 Forest Road, London, E17 4NB.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Motor Vehicles 10 Straight Line
2.

Average number of employees

Average number of employees during the year was 0 (2023 : 0).
3.

Tangible fixed assets

Cost or valuation Motor Vehicles   Total
  £   £
At 01 September 2023 29,544    29,544 
Additions  
Disposals  
At 31 August 2024 29,544    29,544 
Depreciation
At 01 September 2023 2,954    2,954 
Charge for year 2,954    2,954 
On disposals  
At 31 August 2024 5,908    5,908 
Net book values
Closing balance as at 31 August 2024 23,636    23,636 
Opening balance as at 01 September 2023 26,590    26,590 


4.

Creditors: amount falling due within one year

2024
£
  2023
£
Corporation Tax 2,296    598 
Accrued Expenses 400   
Other Creditors   29,544 
Directors' Current Accounts 6,311    1,007 
VAT 3,528    2,376 
12,535    33,525 

7